Hyperion Defi, Inc. · NASDAQ:HYPD
Hyperion Defi — Eyenovia — Investor Presentation (March 2023)
25 slides from Hyperion Defi's investor presentation, Mar 30, 2023
Slide 1: See the future
Z See, the fulure March 2023
Slide 2: Forward-looking Statements
1 Forward - looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forwar d - l ooking statements. Forward - looking statements include, but are not limited to, statements that express our intentions, beliefs, expecta
Slide 3: Eyenovia at a Glance
2 • Horizontal delivery • Precision dose • Digital compliance capabilities Eyenovia at a Glance Eyenovia (NASDAQ | EYEN) is a US Based Medical Device and Ocular Therapeutics Company Optejet ® with microdose array print technology • Patented digital device platform technology • Exciting and diverse p
Slide 4: Eyedropper design has done little to improve usability
3 Over the past 125 years, changes in eyedropper design have done little to improve the usability of topical ophthalmic medications Today’s Eyedropper Bottle Designed for Manufacturing Ease, Not Patient Ease 1800’s Glass Pipette 1900’s Glass Pipette with Bulb and Separate Vial Today Integrated Bottl
Slide 5: Introducing the Optejet
Introducing the Optejet ® Optejet is a drug - device combination product manufactured with a sterile - filled, replaceable drug cartridge 4 Optejet ® with replaceable drug cartridge Spray nozzle with 109 laser - drilled ports Shutter Activation button Ergonomic design Proprietary, pre - filled drug
Slide 6: Ergonomic Design to Improve Usability
5 Ergonomic Design to Improve Usability Horizontal delivery, push button dosing and no protruding tip Eye Dropper Bottle administration requires head - tilting, squeezing, and reliance on gravity Eye Dropper Bottle tips can touch the eye surface Optejet® has a recessed nozzle, protected by a shutter
Slide 7: Precision Dosing to Improve Therapeutic Index
6 Precision Dosing to Improve Therapeutic Index 1 Wirta D. et al, Presentation at 2019 ASCRS meeting | 2 Ianchulev T. et al, Therapeutic Delivery 2018 | 3 Results of a human conjunctival cell line assay study with Tufts Medical Center indicate that the impact of preserved medications delivered with
Slide 8: Optejet Digital Technology to Improve Delivery of Care
7 Optejet Digital Technology to Improve Delivery of Care The Optejet ® is capable of automatically tracking usage Remote Patient Monitoring: More Data May Benefit All Parties PATIENT • Reminders to take medicine • Ability to track compliance progress • Confidence in medication usage PHYSICIAN • Abil
Slide 9: Product Pipeline
8 Product Pipeline * Estimate 1 Out - licensed to Arctic Vision in Greater China and South Korea 2 Estimate from DelveInsight Presbyopia report; December 2020 3 Out - licensed to Bausch+Lomb in the US and Canada, and Arctic Vision in Greater China and South Korea 4 CHAPERONE oversight and costs assu
Slide 10: MydCombi for Pupil Dilation / Mydriasis
9 MydCombi Œ for Pupil Dilation / Mydriasis • Pupil dilation (mydriasis) is part of a comprehensive eye exam and ocular surgery – Estimated 108 million dilations in US annually – Estimated $250 million US market opportunity 1 • Eyedrops are the current standard of care and ripe for innovation – Mult
Slide 11: MydCombi Product Overview
10 MydCombi ΠProduct Overview 1 Denion E. et al, A 5 - Minute Interval between Two Dilating Eye Drops Increases Their Effect. Optom Vis Sci. 2017 Aug 2 Wirta , D. Presented at ASCRS Annual Meeting, 2019, San Diego CA 3 Chayet , A. et al, Evaluation of 2 mydriatic dosing regimens delivered by micro
Slide 12: MydCombi Cash-Pay Diagnostic With Unique Benefits
11 MydCombi ΠCash - Pay Diagnostic With Unique Benefits for the Office and Patient 1. Wilson, F. A., Stimpson, J. P., & Wang, Y. (2015). Inconsistencies exist in national estimates of Eye Care Services Utiliz ati on in the United States. Journal of ophthalmology. Retrieved February 3, 2023, from ht
Slide 13: MicroLine for Presbyopia
12 MicroLine for Presbyopia • Presbyopia is the age - related loss of near vision that occurs as the lens becomes inelastic (hold the menu further away) • 18 million people aged 40 – 55 in the US have presbyopia, with roughly half never having to use glasses earlier in their lives • MicroLine is a l
Slide 14: MicroLine Phase 3 Clinical Results
13 MicroLine Phase 3 Clinical Results • Vision - 1 1 and Vision - 2 2 clinical studies – 6.0x more patients achieved ≥ 3 - line gain on a vision chart in the active group vs. placebo 3 – Well - tolerated with fewer than 2% of patients reporting adverse events – 65% of patients reported seeing improv
Slide 15: MicroLine: Presbyopia Treatment That May Enhance Office Economics
14 MicroLine The Only Presbyopia Treatment in the Optejet that May Enhance Office Economics 1. Population of 40 - 55YO in the US = 60.8MA , 35% of this population has never needed corrected visionB, assumes product will wo rk for 33% of the remaining population A. Published by Erin Duffin, & 30, S.
Slide 16: MicroPine for Childhood Myopic Maculopathy
15 • Begins in early childhood, with genetic link 1 • Elongation of sclera/retina with morbidity and vision problems 2 • Urgent need for FDA - approved drug therapies to slow myopia progression • Atropine may slow myopia progression by at least 60% 3 MicroPine for Childhood Myopic Maculopathy Progre
Slide 17: MicroPine for Childhood Myopic Maculopathy: Compliance
16 • Precision - dosed atropine spray developed specifically for children – Easy, daily use by children 1 – Lower drug volume exposure to enhance comfort and minimize systemic exposure – Potential for pairing with smart devices to track treatment adherence and provide family reminders • Compliance d
Slide 18: MicroPine: A Pediatric Therapy Designed with Children in Mind
17 MicroPine A Pediatric Therapy Designed with Children in Mind Market Receptivity Very high to the device due to the potential benefits it may offer; well accepted by children in the CHAPERONE study Potential Market Size If one assumes the annual cost of these drugs is $2,400, then with 1.9 million
Slide 19: Multiple Commercialization Partners
18 Multiple Commercialization Partners Arctic Vision – A China - based ophthalmic biotech focusing on breakthrough therapies, with a leading portfolio covering pre - clinical stage to commercial stage products Bausch+Lomb – One of the world's largest suppliers of contact lenses, lens care products,
Slide 20: Potential Long Term Income Stream
19 Potential Long Term Income Stream Arctic Vision – MicroPine, MicroLine and MydCombi licensed for Greater China and South Korea; clinical study enrollment underway Bausch+Lomb – MicroPine licensed for the US and Canada. License agreements with a total value of over $90M in payments + royalties
Slide 21: Formosa APNT Technology Collaboration
20 • Eyenovia gains access to Formosa’s APNT Œ formulation technology which opens several new and large market indications for potential expansion of our own development pipeline • APNT Œ (Active Pharmaceutical Nanoparticle Technology) works to reduce particle size leading to improved dissolution, b
Slide 22: Broad Intellectual Property Portfolio
21 Broad Intellectual Property Portfolio • Key claims covered with multiple patents – 18 US Patents Issued; 8 pending – 89 foreign issued; 33 pending – Many in effect beyond 2031 • Clinical data and regulatory approval adds another layer of IP
Slide 23: Financial Snapshot (December 2022)
22 Financial Snapshot (December 2022) Nasdaq: EYEN Common Shares Outstanding 33.6M Equity Grants Outstanding Under Stock Plans 5.0M Warrants 6.1M Fully Diluted Shares 44.7M Cash $29.4M Debt $12.0M
Slide 24: Experienced Leadership Team
23 Experienced Leadership Team Bren Kern Chief Operating Officer For more details, please visit our website Malini Batheja, PhD VP, Pharmaceutical R&D and CMC Regulatory Norbert Lowe VP, Commercial Greg Bennett VP Clinical Operations and Medical Affairs CRR Lauren Gidden AVP, Quality and Regulatory
Slide 25: Investment Summary
24 • Optejet ® platform technology with ergonomic design facilitates ease of use and delivers precise doses – Addresses many problems of conventional eye drops – Protected with a strong intellectual property portfolio • Eyenovia owns a pipeline of products in large therapeutic categories – With mult